Carotid intimal medial thickness in human immunodeficiency virus-infected women: effects of protease inhibitor use, cardiac risk factors, and the metabolic syndrome.

Carotid intimal medial thickness in human immunodeficiency virus-infected women: effects of protease inhibitor use, cardiac risk factors, and the metabolic syndrome. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Carotid intimal medial thickness in human immunodeficiency virus-infected women: effects of protease inhibitor use, cardiac risk factors, and the metabolic syndrome. Abstract Text:

Stine Johnsen,Sara E Dolan,Kathleen V Fitch,Jenna R Kanter,Linda C Hemphill,Jean M Connelly,Robert S Lees,Hang Lee,Steve Grinspoon,

CONTEXT: Little is known regarding carotid intimal medial thickness (IMT) in HIV-infected women and the risk factors for subclinical atherosclerosis in this population, including antiretroviral therapy and the metabolic syndrome. OBJECTIVE: Our objective was to assess carotid IMT in relationship to HIV status and antiretroviral therapy in HIV-infected women in comparison with healthy age- and body mass index (BMI)-matched control subjects. SETTING AND SUBJECTS: The study took place at an academic medical center and included 97 HIV-infected women compared with 86 age- and BMI-matched healthy control subjects. MAIN OUTCOME MEASURES: We assessed carotid IMT, metabolic syndrome, and risk factors for increased IMT. Results: Carotid IMT was not increased in HIV-infected women [0.62 mm (0.57-0.68); median (IQR)] compared with non-HIV-infected women [0.61 mm (0.55-0.68)] matched for age and BMI (P = 0.07) but was increased significantly among HIV patients receiving a protease inhibitor (PI) [0.65 (0.59-0.71) mm] vs. non-PI-treated patients [0.61 (0.57-0.66) mm] (P < 0.05) and vs. control subjects [0.61 (0.55-0.68) mm] (P < 0.05). The prevalence of metabolic syndrome was significantly increased among the HIV-infected women compared with control subjects and particularly in PI- vs. non-PI-treated HIV patients (45 vs. 19%, P = 0.001). Metabolic syndrome score correlated with IMT among non-HIV patients but not among the HIV group. Individual risk factors most strongly associated with IMT in multivariate regression modeling in the control group were age and waist-to-hip ratio, and among the HIV group age and waist circumference. CONCLUSIONS: These data demonstrate increased carotid IMT in HIV-infected women receiving PI therapy, which may be due to associated metabolic abnormalities related to PI therapy or more direct effects of this medication class on the vasculature. Additional studies of the mechanisms by which PI uses results in subclinical atherosclerosis are needed.

Carotid intimal medial thickness in human immunodeficiency virus-infected women: effects of protease inhibitor use, cardiac risk factors, and the metabolic syndrome. Publishing Authors By Initials

S Johnsen,SE Dolan,KV Fitch,JR Kanter,LC Hemphill,JM Connelly,RS Lees,H Lee,S Grinspoon,

For similar musculoskeletal system: muscles: muscle, smooth: muscle, smooth, vascular: tunica media research abstracts see: musculoskeletal system: muscles: muscle, smooth: muscle, smooth, vascular: tunica media research

PUBMED ID PMID:

MEDLINE DATE:

Carotid intimal medial thickness in human immunodeficiency virus-infected women: effects of protease inhibitor use, cardiac risk factors, and the metabolic syndrome. Journal Published:

PUBLICATION TYPE: Research Support, N.I.H., Extr

Journal: The Journal of clinical endocrinology and metaboli

VOLUME: 91

Page Numbers: 4916-24

Journal Abbreviation: J. Clin. Endocrinol. Metab.

ISSN: 0021-972X

DAY: 26

MONTH: 09

YEAR: 2006

Carotid intimal medial thickness in human immunodeficiency virus-infected women: effects of protease inhibitor use, cardiac risk factors, and the metabolic syndrome. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 375362

Carotid intimal medial thickness in human immunodeficiency virus-infected women: effects of protease inhibitor use, cardiac risk factors, and the metabolic syndrome. Keywords Mesh Terms:

KEYWORDS: Tunica Media

MESH TERMS: pathology

Chemical & Substance for Abstract: Carotid intimal medial thickness in human immunodeficiency virus-infected women: effects of protease inhibitor use, cardiac risk factors, and the metabolic syndrome. Information

Substance Name: Protease Inhibitors

Registry Number: 0

Grant and Affiliation Information for Carotid intimal medial thickness in human immunodeficiency virus-infected women: effects of protease inhibitor use, cardiac risk factors, and the metabolic syndrome.

AFFILIATION: Program in Nutritional Metabolism, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.

Country: United States

AGENCY: United States NIDDK

GRANT: R01 DK59535

ACRONYM: DK

MEDLINETA: J Clin Endocrinol Metab

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Carotid intimal medial thickness in human immunodeficiency virus-infected women: effects of protease inhibitor use, cardiac risk factors, and the metabolic syndrome Related Publications

• Carotid intimal medial thickness in human immunodeficiency virus-infected women: effects of protease inhibitor use, cardiac risk factors, and the metabolic syndrome.
• Dietary fat intake and relationship to serum lipid levels in HIV-infected patients with metabolic abnormalities in the HAART era.
• Effects of Growth Hormone-Releasing Factor in HIV-Infected Patients.
• Effects of TNF-alpha neutralization on adipocytokines and skeletal muscle adiposity in the metabolic syndrome.
• Effects of a lifestyle modification program in HIV-infected patients with the metabolic syndrome.
• Effects of a nucleoside reverse transcriptase inhibitor, stavudine, on glucose disposal and mitochondrial function in muscle of healthy adults.
• Effects of metformin and rosiglitazone in HIV-infected patients with hyperinsulinemia and elevated waist/hip ratio.
• Effects of weight, body composition, and testosterone on bone mineral density in HIV-infected women.
• Fracture Prevalence among Human Immunodeficiency Virus (HIV)-Infected Versus Non-HIV-Infected Patients in a Large U.S. Healthcare System.
• Improved triglycerides and insulin sensitivity with 3 months of acipimox in human immunodeficiency virus-infected patients with hypertriglyceridemia.
• Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease.
• Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation.
• Longitudinal anthropometric patterns among HIV-infected and HIV-uninfected women.
• Low-dose physiological growth hormone in patients with HIV and abdominal fat accumulation: a randomized controlled trial.
• Metabolic effects of a growth hormone-releasing factor in patients with HIV.
• Reduced bone density in HIV-infected women.
• Reduced intravertebral bone marrow fat in HIV-infected men.
• Reduced testosterone levels in human immunodeficiency virus-infected women with weight loss and low weight.
• Relation of body composition to body mass index in HIV-infected patients with metabolic abnormalities.